<DOC>
	<DOCNO>NCT02436824</DOCNO>
	<brief_summary>The objective study examine safety , tolerability , efficacy repeat topical administration AB001 topical patch treatment chronic low back pain .</brief_summary>
	<brief_title>A Study Topical Patch ( AB001 ) Patients With Chronic Low Back Pain</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel-group study safety efficacy AB001 topical patch patient chronic low back pain . Subjects meet inclusion criterion randomize 1:1 ratio receive AB001 patch placebo patch . Two AB001 placebo patch give topically daily 14 day . The primary end point change low back pain intensity rat visual analog scale ( VAS ) scale Day 15 , secondary end point include subject global assessment ( SGA ) low back pain , subject global perceive effect ( GPE ) study medication , Roland-Morris Disability Questionnaire ( RMDQ ) , pain assessment subject diary ( Days 1 - 3 ) . Subjects ' safety monitor throughout study , include adverse event ( AE ) incidence severity , laboratory test result ( hematology clinical chemistry ) , vital sign , physical examination .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>1 . Are generally healthy male nonpregnant female , 18 75 year age . 2 . Have body mass index ( BMI ) ≤35 . 3 . Have chronic low back pain least 3 month . 4 . Have low back pain locate inferior twelfth thoracic vertebra ( T12 ) . 5 . Back pain classify , use Quebec Task Force system , either Class 1 Class 2 . 6 . Currently require use analgesic lower back pain ( require least 3 day per week least last 4 week ) . 7 . Have score 30 mm great visual analog scale ( VAS ) score 2 , 3 , 4 Subject Global Assessment ( SGA ) Back Pain Scale Screening . 8 . Are willing discontinue current analgesic 3 15 day washout period . 9 . Have increase least 10 mm score Screening absolute score 50 mm VAS ( ie , VAS ≥ 50 mm ) score 3 4 SGA Back Pain Scale Baseline . 10 . If female , : 1 ) .Of nonchildbearing potential confirmed clinical history sterility , 2 ) .Of childbearing potential , must willing use effective contraception trial entry completion . 11 . Are willing provide write informed consent . 1 . Have chronic low back pain ( CLBP ) due follow pathology : infection , neoplasia , metabolic structural disturbance spine , lumbar radiculopathy , osteoporosis , hip dysplasia , inflammatory arthritis , ankylose spondylitis , Paget 's disease , cauda equine syndrome , gout , pseuodgout , fibromyalgia , postsurgical pain . 2 . Have low back pain cause major trauma . 3 . Have excess hair , tattoo ( ) , dermatologic condition patch application area might interfere efficacy evaluation . 4 . Have surgery low back pain within previous 6 month . 5 . Have clinical depression within 2 year currently undergo treatment depression ; 6 . Have hypersensitivity nonsteroidal antiinflammatory drug ( NSAIDs , include aspirin ) hypersensitivity acetaminophen . 7 . Have use opioids within 72 hour prior Baseline / Day 1 visit course study . 8 . Have use oral injected corticosteroid chronically intermittently within past 60 day ( oral ) , 90 day ( inject ) . 9 . Are current drug alcohol abuser . 10 . Are pregnant , plan become pregnant study , breastfeed . 11 . Have pending workman 's compensation claim , litigation , monetary settlement relate subject 's low back pain . 12 . Have chronic acute medical condition may pose risk safety subject , may interfere assessment safety efficacy trial . 13 . Have history sensitivity component investigational product . 14 . Have know history liver kidney disorder ( hepatic renal insufficiency ) . 15 . Have know history gastric ulcer , gastrointestinal bleeding , significant cardiovascular event . 16 . Have history cancer , treat basal cell carcinoma , within past 5 year . 17 . Use medication , include prescription , OTC , vitamin , herbal and/or mineral supplement , dietary supplement , enzyme alter agent within least14 day prior first treatment trial , may influence trial result . 18 . Use anticoagulant medication within past 30 day , include limited heparin , warfarin/Coumadin , rivaroxaban/Xarelto , dabigatran/Pradaxa , apixaban/Eliquis , etc . 19 . Participation another clinical trial receive investigational product within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>topical patch</keyword>
	<keyword>chronic low back pain</keyword>
</DOC>